Vimarsana
Biggest News Aggregation in the World

Ken Keller News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ken Keller. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ken Keller Today - Breaking & Trending Today

Training tomorrow's healthcare professionals - Vimarsana News

Training tomorrow's healthcare professionals

Nearly three dozen pre-nursing students will soon gain hands-on experience alongside healthcare professionals in a hospital setting through an internship provided by Taft College.

AstraZeneca Plc's Enhertu approved in the US for HER2+ solid tumours - Vimarsana News

AstraZeneca Plc's Enhertu approved in the US for HER2+ solid tumours

AstraZeneca plc and Daiichi Sankyo's Enhertu has gained US approval for treating HER2-positive solid tumours, marking a significant advancement in cancer treatment.

AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor - Vimarsana News

AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor

On Friday, the FDA approved Daiichi Sankyo Ltd’s (OTC:DSKYF) (OTC:DSNKY) and AstraZeneca Plc’s (NASDAQ:AZN) Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for this indicat

Source: yahoo.com
Daiichi Sankyo : ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors (375.5KB -April 05, 2024 at 11:34 pm EDT - Vimarsana News

Daiichi Sankyo : ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors (375.5KB -April 05, 2024 at 11:34 pm EDT

Press Release ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2...

ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors - Vimarsana News

ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Apr 5, 2024--